Mirus Bio receives ISO 13485:2016 certification, underscoring the quality of processes used to support GMP product portfolio. Read more

mirus bio logo

On Demand Webinar

How to Build an AAV Platform that Produces Higher Titers & Percent Full Capsids

Learn the best practices for improving transfection yield across serotypes, media, and cell types from scientists at Mirus Bio and ReciBioPharm

Free Viewing

How to Build an AAV Platform that Produces Higher Titers & Percent Full Capsids

Learn the best practices for improving transfection yield across serotypes, media, and cell types from scientists at Mirus Bio and ReciBioPharm

What you’ll find inside:

  • How upstream processes achieve 2-10X higher titers and percent full capsids with TransIT-VirusGEN® and RevIT™ AAV Enhancer
  • What transfection efficiency results you can expect across multiple serotypes, media, and suspension cell types
  • How to scale from R&D to GMP
  • How smart manufacturing processes enable affordability to drug developers and greater access to therapeutics for patients
  • How upstream can handoff to downstream with higher quality
  • How to cut costs on plasmid DNA
  • How to compare transfection reagents
Previous slide
Next slide

There is an increasing need for more effective, scalable, and cost-conscious manufacturing of recombinant AAV and LV

Selecting the appropriate transfection reagent is paramount for successful viral research, as it directly impacts the efficiency and effectiveness of gene delivery. Additionally, boosting the transfection process with enhancers like Mirus Bio’s RevIT AAV Enhancer can further enhance viral production by increasing titer and percent full capsids, crucial for optimizing your upstream processes.

Efficiency is crucial in virus research. The Mirus Bio FAS team offers invaluable expertise and guidance, assisting your selection of the most suitable transfection reagents and optimizing protocols for your specific virus research needs. Their assistance not only expedites experimental setup but also ensures reliable and reproducible results, empowering you to focus on your core objectives.

“We chose to transfect with TransIT-VirusGEN and RevIT based on the success we saw and in an attempt to maximize production.

The thought here was that with higher yields we would be able to produce a large number of doses per 50 liter bioreactor, therefore reducing the cost per dose.”

“We chose to transfect with TransIT-VirusGEN and RevIT based on the success we saw and in an attempt to maximize production.

The thought here was that with higher yields we would be able to produce a large number of doses per 50 liter bioreactor, therefore reducing the cost per dose.”

Chris Brown
Senior Scientist of Process Development
ReciBioPharm

Start scaling your upstream efforts today

Start scaling your upstream efforts today